Clinical Trial Update: A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing the safety of once-daily single-tablet abacavir/lamivudine versus twice-daily separate tablets in HIV infection. The study has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Epivir (Lamivudine)
• Ziagen (Abacavir)

Snippet

Sponsor: GlaxoSmithKline | Conditions: HIV Infection | Phase 3 | Status: COMPLETED